Global Nitinol Medical Devices Market Is Estimated to Witness High Growth Owing to Rising Usage in Minimally Invasive Surgeries and Innovation in Device Design
The Nitinol Medical Devices Market is estimated to be valued at USD 1.8 Bn in 2024 and is expected to exhibit a CAGR of 10.4% over the forecast period 2024-2031. Nitinol medical devices find wide application in cardiovascular, orthopedic and other medical fields owing to its shape memory and super elastic properties. Furthermore, growing demand for minimally invasive procedures is also expected to propel market growth during the forecast period.
Market Dynamics:
Rising usage of minimally invasive surgeries: Minimally invasive surgeries require medical devices with enhanced flexibility and strength. Properties like shape memory and super elasticity of nitinol alloys make them extremely suitable for manufacturing guidewires, stents and other medical devices used in minimally invasive procedures. This is expected to drive the demand for nitinol medical devices. Innovation in device design: Manufacturers are continuously innovating and developing advanced nitinol-based medical devices with enhanced capabilities. Features like enhanced flexibility, kink-resistance and deliverability allow complex procedures to be performed. Innovative nitinol device designs are expanding medical applications which is further fueling the market growth.
Major Driver: Growing Prevalence of Target Diseases is Driving Demand for Nitinol Medical Devices
The rising prevalence of target diseases such as cardiovascular diseases and neurological disorders is a major driver for the growth of the nitinol medical devices market. Cardiovascular diseases are the leading cause of death globally. According to WHO, cardiovascular diseases account for over 17.9 million deaths per year, a number that is expected to grow to over 23.6 million by 2030. The increasing risk factors for cardiovascular diseases like obesity, diabetes and lack of physical activity are contributing to this rising prevalence. Nitinol stents and other cardiovascular devices have emerged as effective treatment options, driving increased demand. Similarly, neurological disorders are also on the rise. Over 50 million people suffer from epilepsy worldwide. The growing geriatric population is another key factor driving the need for nitinol medical devices across various therapeutic areas.
Technological Innovations Leading to Development of New Applications
Constant technological advancements are leading to the development of nitinol for new medical applications, thereby propelling market growth. Research efforts are underway to develop nitinol alloys with enhanced properties. New surface modification techniques are being explored to improve biocompatibility. Additive manufacturing technologies like 3D printing are enabling more complex nitinol device designs. Researchers are studying the potential of using nitinol's shape memory effect for applications in drug delivery systems. All such technological innovations are expanding the scope of nitinol and fueling market expansion. Novel applications under research include using nitinol ribbons for correction of clubfoot deformity in children and developing heart pumps made of nitinol. As new applications get validated and commercialized, they will create untapped market opportunities.
High Manufacturing Costs Pose Significant Restraint
One of the key challenges faced by players in the nitinol medical devices market is its high manufacturing cost. Producing nitinol alloys and fabricating them into intricate medical device designs requires sophisticated technology and manufacturing expertise. This makes nitinol at least 3-4 times more expensive to produce than comparable stainless steel. The costs arise from the specialized production methods needed for achieving the unique shape memory and superelastic properties. High capital investments are also required to set up facilities with capabilities for processing nitinol. Further, stringent regulatory approvals for new nitinol alloys and manufacturing processes add to the overall costs. Such high production costs are a major restraint for widespread nitinol adoption, especially in price-sensitive markets.
Reimbursement Issues Hamper Market Adoption Rates
Reimbursement issues also act as a restraint on the nitinol medical devices market growth potential. Since nitinol devices generally command a higher price tag than conventional alternatives, securing adequate insurance coverage and reimbursement is challenging. Reimbursement policies often do not cover the additional costs associated with nitinol devices. Furthermore, reimbursement guidelines differ greatly across regions and countries. In developing nations especially, financial assistance for such specialized implantable devices is limited. This results in lower affordability for both patients and providers. Without proper coverage support through public or private payers, many providers are hesitant to use expensive nitinol implants. Addressing fluctuating and unpredictable reimbursement landscapes continues to be a barrier to market expansion.
Growing Focus on Minimally Invasive Procedures Presents Opportunity
One of the key opportunities for players in the nitinol medical devices market lies in the growing preference for minimally invasive surgeries. Nitinol's superelastic and shape memory properties make it highly suitable for navigating complex anatomy during minimally invasive procedures. Its biocompatibility also allows for developing tiny nitinol devices. With advantages like reduced trauma, scarring and shorter hospital stays, minimally invasive surgeries are becoming the standard of care for various conditions. This shift towards minimally invasive therapies is driving increased research into nitinol guidewires, catheters, implants and other sophisticated nitinol devices. Manufacturers can capitalize on this growing demand by developing innovative nitinol products tailored for various MIS applications.
Potential in Emerging Economies with Rising Disease Burden
Emerging economies in regions like Asia Pacific, Latin America and Africa present a major market opportunity for players. These nations are facing rapid epidemiological transition with a growing burden of chronic diseases. At the same time, their healthcare infrastructures are heavily investing in specialized technologies. Countries are working towards expanding health insurance coverage as well. Nitinol product manufacturers can leverage these dynamics by customizing their portfolio for resource-constrained settings and partnering with regional distributors. Offering capacity building programs, flexible financing options and transitional partnerships with
Link - https://www.coherentmarketinsights.com/market-insight/nitinol-medical-devices-market-5400
Key Development
- In November 2022, Alleima, Materials Technology company has entered into an agreement to acquire Endosmart Gesellschaft für Medizintechnik GmbH (Endosmart), a German-based manufacturer of medical devices and components made from the shape memory alloy nitinol. Endosmart's offerings include kidney stone retrieval baskets and snares, breast cancer tumor markers, and surgical instruments. Primarily serving urology, oncology, cardiology, orthopedics, and vascular applications, Endosmart will become part of Alleima's Kanthal division.
- In May 2022, Stryker Corporation introduced its EasyFuse Dynamic Compression System, utilizing the nickel-titanium alloy known as Nitinol. The system leverages Nitinol's robustness and shape memory properties to simplify surgeries and minimize waste in the operating room
- In January 2022, Cook Medical, medical device company has been granted Breakthrough Device designation by the US Food and Drug Administration (FDA) for a novel drug-eluting stent intended for below-the-knee (BTK) use. This innovative stent is developed to address the needs of patients suffering from chronic limb-threatening ischemia (CLTI).
- In January 2023, Resonetics a pioneer in advanced engineering has agreed to acquire Memry Corporation and SAES Smart Materials, Inc., nitinol supply chain companies, both companies are based in the United States and specialize in nitinol-based medical devices. The transaction, valued at US$900 million, is backed by investment firms Carlyle and GTCR.
Key Players: Boston Scientific Corporation, Abbott Laboratories, Medtronic plc, Cook Medical, B. Braun Melsungen AG, Terumo Corporation, Endologix, Inc., Stryker Corporation, Confluent Medical Technologies, IntraPace, Inc., Miach Orthopaedics, Inc., DynaFlex, Nitinol Development Corporation, Memry Corporation, Admedes Schuessler GmbH, Euroflex GmbH, G. Rau GmbH & Co. KG, and Fort Wayne Metals.
